Parameswaran Hari

26.6k total citations · 1 hit paper
420 papers, 7.8k citations indexed

About

Parameswaran Hari is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Parameswaran Hari has authored 420 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 267 papers in Hematology, 187 papers in Oncology and 181 papers in Molecular Biology. Recurrent topics in Parameswaran Hari's work include Multiple Myeloma Research and Treatments (202 papers), Hematopoietic Stem Cell Transplantation (89 papers) and CAR-T cell therapy research (83 papers). Parameswaran Hari is often cited by papers focused on Multiple Myeloma Research and Treatments (202 papers), Hematopoietic Stem Cell Transplantation (89 papers) and CAR-T cell therapy research (83 papers). Parameswaran Hari collaborates with scholars based in United States, United Kingdom and Germany. Parameswaran Hari's co-authors include Binod Dhakal, Mehdi Hamadani, Nirav N. Shah, Saurabh Chhabra, Marcelo C. Pasquini, Anita D’Souza, Bryon D. Johnson, William R. Drobyski, Paul G. Richardson and David H. Vesole and has published in prestigious journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Parameswaran Hari

401 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

2020 318 citations Nirav N. Shah, Bryon D. Johnson et al. profile →

Peers

Countries citing papers authored by Parameswaran Hari

Since Specialization

Citations

This map shows the geographic impact of Parameswaran Hari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Parameswaran Hari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Parameswaran Hari more than expected).

Fields of papers citing papers by Parameswaran Hari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Parameswaran Hari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Parameswaran Hari. The network helps show where Parameswaran Hari may publish in the future.

Co-authorship network of co-authors of Parameswaran Hari

This figure shows the co-authorship network connecting the top 25 collaborators of Parameswaran Hari. A scholar is included among the top collaborators of Parameswaran Hari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Parameswaran Hari. Parameswaran Hari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma 2025 ·Journal of Clinical Oncology ·Nirav N. Shah, (unknown), Bryon D. Johnson, Anikó Szabó, Fateeha Furqan, (unknown), Dina Schneider, Mauricio Vargas‐Cortes, (unknown), Michael B. Dwinell, Katie Palen, Walter Longo, Peiman Hematti, Anthony E. Zamora, Parameswaran Hari, (unknown), Ashley M. Cunningham, Mehdi Hamadani, Timothy S. Fenske	2
2	CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma 2024 ·Blood ·(unknown), Kishan Kumar Nyati, Tarang Sharma, Binod Dhakal, Meera Mohan, Parameswaran Hari, Sabarinath Venniyil Radhakrishnan	1
3	OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. 2024 ·Journal of Clinical Oncology ·Rodabe N. Amaria, Jennifer L. McQuade, Michael A. Davies, Isabella Claudia Glitza, (unknown), Erik N. K. Cressman, (unknown), Roland L. Bassett, Sapna P. Patel, Adi Diab, Hussein A. Tawbi, Michael K. Wong, Alexandra P. Ikeguchi, Cara Haymaker, (unknown), Madan Jagasia, Giridharan Ramsingh, Prakash Prabhakar, (unknown), Parameswaran Hari	17
4	Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing 2024 ·Blood Cancer Journal ·Jianrong Li, Shahram Arsang‐Jang, Yan Cheng, Fumou Sun, Anita D’Souza, Binod Dhakal, Parameswaran Hari, (unknown), (unknown), Yong Li, Raúl Urrutia, (unknown), John D. Shaughnessy, Siegfried Janz, Jing Dong, Chao Cheng	4
5	Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program 2022 ·Bone Marrow Transplantation ·Mark A. Schroeder, Parameswaran Hari, (unknown), Dilan Paranagama, Valkal Bhatt, John F. DiPersio	7
6	Outcomes of Hematopoietic Progenitor Cells Mobilization and Collection Following Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone Induction in Newly Diagnosed Multiple Myeloma 2021 ·Transplantation and Cellular Therapy ·Saurabh Chhabra, (unknown), Rebecca Silbermann, Bhagirathbhai Dholaria, Timothy M. Schmidt, Susan Bal, Luciano J. Costa, Bicky Thapa, Binod Dhakal, Anita D’Souza, Eva Medvedova, Parameswaran Hari, Natalie S. Callander	0
7	Clinical and Manufacturing Outcomes of LV20.19 CAR T-Cells Expanded in IL-2 Versus IL-7 and IL-15 2021 ·Transplantation and Cellular Therapy ·Nirav N. Shah, Joanna Zurko, Timothy S. Fenske, Mehdi Hamadani, Dina Schneider, Huiqing Xu, (unknown), Boro Dropulić, Bryon D. Johnson, Parameswaran Hari	1
8	Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma 2021 ·Blood Advances ·Meera Mohan, (unknown), Binod Dhakal, Sabarinath Venniyil Radhakrishnan, Saurabh Chhabra, Anita D’Souza, Parameswaran Hari	34
9	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges 2020 ·Bone Marrow Transplantation ·Binod Dhakal, Parameswaran Hari, Saad Z. Usmani, Mehdi Hamadani	23
10	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta‐analysis of phase 3 randomized controlled trials 2020 ·Cancer ·Binod Dhakal, (unknown), Smith Giri, Anikó Szabó, Timothy L. Smunt, Sanjoy Ghose, (unknown), Madan Raj Aryal, Mehdi Hamadani, Saurabh Chhabra, Siegfried Janz, Anita D’Souza, Parameswaran Hari	4
11	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial 2020 ·Blood Advances ·Jennifer M. Knight, J. Douglas Rizzo, Parameswaran Hari, Marcelo C. Pasquini, (unknown), Anita D’Souza, Brent R. Logan, Mehdi Hamadani, Saurabh Chhabra, Binod Dhakal, Nirav N. Shah, (unknown), Mary M. Horowitz, Steve W. Cole	39
12	Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation 2019 ·Biology of Blood and Marrow Transplantation ·Abraham S. Kanate, Anikó Szabó, Renju Raj, (unknown), (unknown), Nilay Shah, Kelly G. Ross, Aaron Cumpston, Michael Craig, Marcelo C. Pasquini, Nirav N. Shah, Parameswaran Hari, Mehdi Hamadani, Saurabh Chhabra	14
13	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting 2018 ·Biology of Blood and Marrow Transplantation ·Guru Subramanian Guru Murthy, Parameswaran Hari, Anikó Szabó, Marcelo C. Pasquini, (unknown), Muhammad Ali Khan, Sameem Abedin, Saurabh Chhabra, Binod Dhakal, Anita D’Souza, William R. Drobyski, J. Douglas Rizzo, Lyndsey Runaas, Nirav N. Shah, Bronwen E. Shaw, Wael Saber, Timothy S. Fenske, Mehdi Hamadani	24
14	Instrumental variable with competing risk model 2017 ·Statistics in Medicine ·Cheng Zheng, Ran Dai, Parameswaran Hari, Mei‐Jie Zhang	9
15	Chemo-Mobilization in Myeloma—Diminishing Returns in the Era of Novel Agent Induction? 2017 ·Biology of Blood and Marrow Transplantation ·Parameswaran Hari	0
16	Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation 2017 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Narendranath Epperla, Namrata Shah, (unknown), George Carrum, Parameswaran Hari, Sai Ravi Pingali, Mehdi Hamadani, Reem Karmali, Timothy S. Fenske	8
17	CAR-T Cell Production Using the Clinimacs® Prodigy System 2016 ·Blood ·Fenlu Zhu, Nirav N. Shah, Huiqing Xu, Dina Schneider, Rimas J. Orentas, Boro Dropulić, Parameswaran Hari, Carolyn A. Keever-Taylor	14
18	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age 2016 ·Clinical Lymphoma Myeloma & Leukemia ·Binod Dhakal, Ariel Ann Nelson, Guru Subramanian Guru Murthy, Raphael Fraser, Daniel Eastwood, Mehdi Hamadani, (unknown), Anita D’Souza, Parameswaran Hari	13
19	Plerixafor and Abbreviated-Course Granulocyte Colony–Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis 2014 ·Biology of Blood and Marrow Transplantation ·Binod Dhakal, Christopher Strouse, Anita D’Souza, Carlos Arce‐Lara, (unknown), Daniel Eastwood, Marcelo C. Pasquini, Wael Saber, William R. Drobyski, J. Douglas Rizzo, Parameswaran Hari, Mehdi Hamadani	18
20	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting 2008 ·Blood ·Marcello Rotta, Barry E. Storer, Firoozeh Sahebi, Judith A. Shizuru, Benedetto Bruno, Thoralf Lange, Edward Agura, Peter A. McSweeney, Michael A. Pulsipher, Parameswaran Hari, Richard T. Maziarz, Thomas R. Chauncey, Frederick R. Appelbaum, Mohamed L. Sorror, William Bensinger, Brenda M. Sandmaier, Rainer Storb, David G. Maloney	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact